Table 2.
Involved systems and signal strength for darunavir and its boosted agents based on system organ class.
| SOCa | RORb (95%CI) | PRRc (χ2) | ICd (IC-2SD) |
|---|---|---|---|
| Hepatobiliary disorders | 3.03 (2.88–3.20) | 2.72 (1882.57) | 1.44 (1.41) |
| Renal and urinary disorders | 2.45 (2.33–2.57) | 2.19 (1341.86) | 1.13 (1.10) |
| Metabolism and nutrition disorders | 2.44 (1.35–1.56) | 2.41 (103.75) | 0.50 (0.47) |
| Endocrine disorders | 13.92 (12.43–15.59) | 13.55 (3585.85) | 3.69 (3.65) |
| Eye disorders | 21.44 (18.63–24.66) | 21.05 (3783.56) | 4.24 (4.20) |
| Cardiac disorders | 2.03 (1.01–2.24) | 2.04 (4.05) | 0.04 (0.01) |
| Musculoskeletal and connective tissue disorders | 7.96 (7.33–8.65) | 7.58 (3374.00) | 2.90 (2.87) |
| Nervous system disorders | 7.16 (6.48–7.90) | 6.93 (2061.09) | 2.76 (2.73) |
| Skin and subcutaneous tissue disorders | 10.90 (10.28–11.57) | 9.75 (9877.79) | 3.26 (3.23) |
| Gastrointestinal disorders | 10.10 (9.58–10.65) | 8.71 (11,314.98) | 3.11 (3.08) |
| Pregnancy, puerperium and perinatal conditions | 12.63 (12.05–13.24) | 10.26 (18,528.56) | 3.34 (3.31) |
aSOC System organ class.
bROR reporting odds ratio. The lower limits of the 95% CI of the ROR greater than 1 indicated statistically significant RORs.
cPRR proportional reporting ratio. PRR and χ2 greater than 2 and 4 respectively indicated statistically significant PRRs.
dInformation component. The signal was statistically significant when IC-2SD > 0.